FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361946870> ?p ?o ?g. }

• W4361946870 abstract "<div>AbstractPurpose:<p>Pancreatic ductal adenocarcinoma (PDAC) remains a deadly disease urgently requiring new treatments. Overexpression of the protein transporter exportin-1 (XPO1) leads to mislocalization of tumor-suppressor proteins (TSP) and their inactivation. Earlier, we showed that blocking XPO1 by CRISPR/Cas9 validated Selective Inhibitor of Nuclear Export (SINE) compounds (selinexor and analogs) restores the antitumor activity of multiple TSPs leading to suppression of PDAC <i>in vitro</i> and in orthotopic models.</p>Experimental Design:<p>We evaluate the synergy between SINE compounds and standard-of-care treatments in preclinical models and in a PDAC Phase Ib trial.</p>Results:<p>SINE compounds synergize with gemcitabine (GEM) and nanoparticle albumin–bound (nab)-paclitaxel leading to suppression of PDAC cellular growth and cancer stem cell (CSC) spheroids disintegration. Label-free quantitative proteome profiling with nuclear and cytoplasmic enrichment showed superior enhancement in nuclear protein fraction in combination treatment. Selinexor inhibited the growth of PDAC CSC and two patient-derived (PDX) subcutaneous xenografts. Selinexor–GEM–nab-paclitaxel blocked PDX and orthotopic tumor growth. In a phase 1b study (NCT02178436), 9 patients were exposed to selinexor (60 mg oral) with GEM (1,000 mg/m² i.v.) and nab-paclitaxel (125 mg/m² i.v.) on days 1, 8, and 15 of 28-day cycle. Two patients showed partial response, and 2 had stable disease. An outstanding, durable objective response was observed in one of the responders with progression-free survival of 16 months and overall survival of 22 months.</p>Conclusions:<p>Our preclinical and ongoing clinical study lends support to the use of selinexor–GEM–nab-paclitaxel as an effective therapy for metastatic PDAC.</p></div>" @default.
• W4361946870 created "2023-04-05" @default.
• W4361946870 creator A5002142386 @default.
• W4361946870 creator A5011312785 @default.
• W4361946870 creator A5011817630 @default.
• W4361946870 creator A5013768762 @default.
• W4361946870 creator A5037090507 @default.
• W4361946870 creator A5038465132 @default.
• W4361946870 creator A5044781652 @default.
• W4361946870 creator A5050907029 @default.
• W4361946870 creator A5056962753 @default.
• W4361946870 creator A5069522076 @default.
• W4361946870 creator A5076913129 @default.
• W4361946870 creator A5078114527 @default.
• W4361946870 creator A5080351994 @default.
• W4361946870 creator A5085956632 @default.
• W4361946870 creator A5089628525 @default.
• W4361946870 date "2023-03-31" @default.
• W4361946870 modified "2023-10-18" @default.
• W4361946870 title "Data from Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma" @default.
• W4361946870 doi "https://doi.org/10.1158/1078-0432.c.6528758" @default.
• W4361946870 hasPublicationYear "2023" @default.
• W4361946870 type Work @default.
• W4361946870 citedByCount "0" @default.
• W4361946870 crossrefType "posted-content" @default.
• W4361946870 hasAuthorship W4361946870A5002142386 @default.
• W4361946870 hasAuthorship W4361946870A5011312785 @default.
• W4361946870 hasAuthorship W4361946870A5011817630 @default.
• W4361946870 hasAuthorship W4361946870A5013768762 @default.
• W4361946870 hasAuthorship W4361946870A5037090507 @default.
• W4361946870 hasAuthorship W4361946870A5038465132 @default.
• W4361946870 hasAuthorship W4361946870A5044781652 @default.
• W4361946870 hasAuthorship W4361946870A5050907029 @default.
• W4361946870 hasAuthorship W4361946870A5056962753 @default.
• W4361946870 hasAuthorship W4361946870A5069522076 @default.
• W4361946870 hasAuthorship W4361946870A5076913129 @default.
• W4361946870 hasAuthorship W4361946870A5078114527 @default.
• W4361946870 hasAuthorship W4361946870A5080351994 @default.
• W4361946870 hasAuthorship W4361946870A5085956632 @default.
• W4361946870 hasAuthorship W4361946870A5089628525 @default.
• W4361946870 hasBestOaLocation W43619468702 @default.
• W4361946870 hasConcept C121608353 @default.
• W4361946870 hasConcept C126322002 @default.
• W4361946870 hasConcept C185592680 @default.
• W4361946870 hasConcept C2777292972 @default.
• W4361946870 hasConcept C2780210213 @default.
• W4361946870 hasConcept C2780258809 @default.
• W4361946870 hasConcept C502942594 @default.
• W4361946870 hasConcept C71924100 @default.
• W4361946870 hasConcept C98274493 @default.
• W4361946870 hasConceptScore W4361946870C121608353 @default.
• W4361946870 hasConceptScore W4361946870C126322002 @default.
• W4361946870 hasConceptScore W4361946870C185592680 @default.
• W4361946870 hasConceptScore W4361946870C2777292972 @default.
• W4361946870 hasConceptScore W4361946870C2780210213 @default.
• W4361946870 hasConceptScore W4361946870C2780258809 @default.
• W4361946870 hasConceptScore W4361946870C502942594 @default.
• W4361946870 hasConceptScore W4361946870C71924100 @default.
• W4361946870 hasConceptScore W4361946870C98274493 @default.
• W4361946870 hasLocation W43619468701 @default.
• W4361946870 hasLocation W43619468702 @default.
• W4361946870 hasOpenAccess W4361946870 @default.
• W4361946870 hasPrimaryLocation W43619468701 @default.
• W4361946870 hasRelatedWork W1430115117 @default.
• W4361946870 hasRelatedWork W1975153720 @default.
• W4361946870 hasRelatedWork W2001578098 @default.
• W4361946870 hasRelatedWork W2006547351 @default.
• W4361946870 hasRelatedWork W2024463098 @default.
• W4361946870 hasRelatedWork W2091019843 @default.
• W4361946870 hasRelatedWork W2111262996 @default.
• W4361946870 hasRelatedWork W2165480504 @default.
• W4361946870 hasRelatedWork W2168580276 @default.
• W4361946870 hasRelatedWork W2324819167 @default.
• W4361946870 isParatext "false" @default.
• W4361946870 isRetracted "false" @default.
• W4361946870 workType "article" @default.